Research therapeutics: protein kinase inhibitors - Qurient Therapeutics

Drug Profile

Research therapeutics: protein kinase inhibitors - Qurient Therapeutics

Alternative Names: Axl kinase inhibitors - Qurient Therapeutics; CDK7 inhibitors - Qurient Therapeutics; CSF1R inhibitors; Cyclin-dependent kinase 7 inhibitors - Qurient Therapeutics; Mer kinase inhibitors - Qurient Therapeutics; Q-701

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Max Planck Innovation; The Lead Discovery Center; The Max Planck Institute of Biochemistry; Vichem Chemie
  • Developer Max Planck Innovation; Qurient Co; The Lead Discovery Center; The Max Planck Institute of Biochemistry
  • Class Anti-inflammatories; Antineoplastics; Antivirals
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Colony stimulating factor receptor antagonists; Cyclin-dependent kinase inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; Proto-oncogene protein c-mer inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Inflammation; Viral infections

Most Recent Events

  • 26 Oct 2017 Qurient plans to file an IND application for Q 701
  • 26 Oct 2017 Pharmacodynamics, immunogenicity and adverse events data for Q 701 from a preclinical trial in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 26 Oct 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top